{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:29:06Z","timestamp":1776407346743,"version":"3.51.2"},"reference-count":26,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,8,31]],"date-time":"2012-08-31T00:00:00Z","timestamp":1346371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>The effect of disease\u2010modifying antirheumatic drugs (<jats:styled-content style=\"fixed-case\">DMARD<\/jats:styled-content>s) in ankylosing spondylitis (<jats:styled-content style=\"fixed-case\">AS<\/jats:styled-content>) is still controversial. We aimed to evaluate the efficacy of sulphasalazine (<jats:styled-content style=\"fixed-case\">SSZ<\/jats:styled-content>) mono\u2010 or combination therapy with methotrexate (<jats:styled-content style=\"fixed-case\">MTX<\/jats:styled-content>) in <jats:styled-content style=\"fixed-case\">AS<\/jats:styled-content> patients naive to anti\u2010tumor necrosis factor alpha (<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\u03b1) agents.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with <jats:styled-content style=\"fixed-case\">AS<\/jats:styled-content> (<jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>87, male\u00a0:\u00a0female, 46\u00a0:\u00a041) treated with <jats:styled-content style=\"fixed-case\">SSZ<\/jats:styled-content> (<jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>61) or <jats:styled-content style=\"fixed-case\">SSZ<\/jats:styled-content>\u00a0+\u00a0<jats:styled-content style=\"fixed-case\">MTX<\/jats:styled-content> (<jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>26) combination and a documented 6\u2010month follow\u2010up were evaluated retrospectively. Disease activity was assessed by the <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>ath <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>nkylosing <jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>pondylitis <jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>isease <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>ctivity <jats:styled-content style=\"fixed-case\">I<\/jats:styled-content>ndex (<jats:styled-content style=\"fixed-case\">BASDAI<\/jats:styled-content>), <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>\u2010reactive protein and erythrocyte sedimentation rate. Requirement for anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\u03b1 therapy was assessed after 6\u00a0months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Mean (<jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content>) age was 43.0 (11.0) versus 40.2 (11.1) and disease duration was 11.0 (8.6) versus 8.2 (5.2) years, in the SSZ and <jats:styled-content style=\"fixed-case\">SSZ<\/jats:styled-content>\u00a0+\u00a0<jats:styled-content style=\"fixed-case\">MTX<\/jats:styled-content> groups, respectively. Initially, 59% (34\/61) of the patients in <jats:styled-content style=\"fixed-case\">SSZ<\/jats:styled-content> monotherapy and 68% (17\/26) in the combination arm had <jats:styled-content style=\"fixed-case\">BASDAI<\/jats:styled-content> &gt;\u00a04. At the end of the study, <jats:styled-content style=\"fixed-case\">BASDAI<\/jats:styled-content> scores decreased similarly in both groups (mono: 1.4 [\u20137\u20136] versus combination: 0.7 [\u20133\u20136] <jats:italic>P\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0.2). <jats:styled-content style=\"fixed-case\">BASDAI<\/jats:styled-content> was &gt;\u00a04 in 32.8% (20\/61) of patients in the <jats:styled-content style=\"fixed-case\">SSZ<\/jats:styled-content> monotherapy and in 44% (11\/26) in the combination arm. Only 4 (6.6%) patients in the <jats:styled-content style=\"fixed-case\">SSZ<\/jats:styled-content> group and 2 (7.7%) in the ombination arm were switched to anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\u03b1 therapies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>A significant subset of our <jats:styled-content style=\"fixed-case\">AS<\/jats:styled-content> patients responded to <jats:styled-content style=\"fixed-case\">SSZ<\/jats:styled-content> mono or <jats:styled-content style=\"fixed-case\">SSZ<\/jats:styled-content>\u00a0+\u00a0<jats:styled-content style=\"fixed-case\">MTX<\/jats:styled-content> combination therapies at 6\u00a0months follow\u2010up. Using <jats:styled-content style=\"fixed-case\">BASDAI<\/jats:styled-content>, the requirement for biological therapies decreased by 21\u201324%. In <jats:styled-content style=\"fixed-case\">AS<\/jats:styled-content> patients, including those with axial involvement only, <jats:styled-content style=\"fixed-case\">DMARD<\/jats:styled-content> therapy may be a reasonable first alternative to anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\u03b1 therapy and may delay the switch to biologic agents.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1756-185x.2012.01817.x","type":"journal-article","created":{"date-parts":[[2012,8,31]],"date-time":"2012-08-31T08:39:56Z","timestamp":1346402396000},"page":"526-530","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Conventional <scp>DMARD<\/scp> therapy (methotrexate\u2010sulphasalazine) may decrease the requirement of biologics in routine practice of ankylosing spondylitis patients: A real\u2010life experience"],"prefix":"10.1111","volume":"15","author":[{"given":"Meryem","family":"Can","sequence":"first","affiliation":[{"name":"Department of Rheumatology Pendik Training and Research Hospital Marmara University Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibel Z.","family":"Ayd\u0131n","sequence":"additional","affiliation":[{"name":"Rheumatology Unit Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adil","family":"Ni\u011fdelio\u011flu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Pendik Training and Research Hospital Marmara University Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamir","family":"Atag\u00fcnd\u00fcz","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Pendik Training and Research Hospital Marmara University Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haner","family":"Direskeneli","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Pendik Training and Research Hospital Marmara University Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,8,31]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60635-7"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.020503"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.041137"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-107-2-358"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-010-1599-7"},{"key":"e_1_2_5_7_1","first-page":"1482","article-title":"Meta\u2010analysis of sulfasalazine in ankylosing spondylitis","volume":"17","author":"Ferraz MB","year":"1990","journal-title":"J Rheumatol"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151027"},{"issue":"4","key":"e_1_2_5_9_1","first-page":"cd004524","article-title":"Metotrexate for anklylosing spondylitis","author":"Chen J","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh595"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.040758"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24507"},{"key":"e_1_2_5_13_1","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett S","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"e_1_2_5_15_1","first-page":"1104","article-title":"Methotrexate in severe ankylosing spondylitis: an open study","volume":"22","author":"Creemers MC","year":"1995","journal-title":"J Rheumatol"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/030097400750002021"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s100670050027"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.054098"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.11.1330"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/030097401753180318"},{"key":"e_1_2_5_21_1","first-page":"1568","article-title":"Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial","volume":"31","author":"Gonzalez\u2010Lopez L","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.293.6552.911"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380507"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C"},{"key":"e_1_2_5_25_1","first-page":"2335","article-title":"Sulfasalazine in the treatment of ankylosing spondylitis: a twenty\u2010six\u2010week, placebo\u2010controlled clinical trial","volume":"42","author":"Nissila M","year":"1988","journal-title":"Arthritis Rheum"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.052878"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30223"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1756-185X.2012.01817.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1756-185X.2012.01817.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T10:53:10Z","timestamp":1698749590000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1756-185X.2012.01817.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,31]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["10.1111\/j.1756-185X.2012.01817.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1756-185x.2012.01817.x","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,31]]},"assertion":[{"value":"2012-08-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}